Drug
Emtricitabine clinical trials
Also written Emtriva and FTC.
- studies test it
- 177
- open now
- 10
- in phase 3
- 49
- first study started
- 1999
Keep track of what changes. Save the Emtricitabine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Other names
- FTC
- 4
Studies by the year they started
174 studies that test it; most in 2015 (22)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 6 |
| 2006 | 4 |
| 2007 | 5 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 8 |
| 2013 | 7 |
| 2014 | 9 |
| 2015 | 22 |
| 2016 | 12 |
| 2017 | 9 |
| 2018 | 10 |
| 2019 | 9 |
| 2020 | 12 |
| 2021 | 12 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 7 |
| 2025 | 4 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 28
- Phase 2
- 33
- Phase 3
- 49
- Phase 4
- 63
- No phase
- 13
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 63 · Other 114
Gilead Sciences (43) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Asian-Pacific Alliance of Liver Disease, Beijing (5) · French National Agency for Research on AIDS and Viral Hepatitis (4) · Kirby Institute (4) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (4) · Juan A. Arnaiz (4) · University of California, San Francisco (3)
Often tested with
Tested in the same studies.
Tenofovir (79) · Tenofovir alafenamide (70) · Bictegravir (37) · Cobicistat (30) · Elvitegravir (21) · Darunavir (17) · Efavirenz (14) · Ritonavir (12)
Studies
Open first, then newest update. How each study uses Emtricitabine is read from its arms, and is right about nine times in ten.
Testing it · 177
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as E/C/F/TAF
- A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingPhase 2Gilead SciencesNCT07645287Written as B/F/TAF
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingPhase 2/3Gilead SciencesNCT07708727Written as B/F/TAF
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidERecruitingPhase 4CAN Community HealthNCT07476339Written as Bictegravir, emtricitabine, and tenofovir alafenamide
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Emtricitabine (FTC)
- Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07678268Written as Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine
- Antiviral Clinical Trial for Long Covid-19RecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT06511063Written as tenofovir disoproxil/emtricitabine
- Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of ADRecruitingPhase 1Butler HospitalNCT04500847Written as Emtriva Capsule
- The Antiretroviral Speed Access Program Switch (ASAP-Switch) StudyNot yet recruitingPhase 4McGill University Health Centre/Research Institute of the McGill University Health CentreNCT06375304Written as B/F/TAF
- Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan AfricaNot yet recruitingPhase 3MRC/UVRI and LSHTM Uganda Research UnitNCT06133686Written as Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionActive, not recruitingPhase 3Gilead SciencesNCT04994509Written as F/TAF
- Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 InfectionTerminatedPhase 3Gilead SciencesNCT02842086Written as F/TAF
- Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVActive, not recruitingPhase 1Gilead SciencesNCT07055451Written as B/F/TAF
- A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)CompletedPhase 1Merck Sharp & Dohme LLCNCT07532304Written as Bictegravir/emtricitabine/tenofovir alafenamide
- IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration ProjectCompletedPhase 4Rutgers, The State University of New JerseyNCT03058835Written as tenofovir disoproxil and emtricitabine
- Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore StudyActive, not recruitingPhase 1National University Hospital, SingaporeNCT07210528Written as Emtricitabine (FTC)
- Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV InfectionActive, not recruitingPhase 4University of California, San FranciscoNCT02656511Written as Emtricitabine/Tenofovir
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyActive, not recruitingPhase 3Gilead SciencesNCT06333808Written as B/F/TAF
- Biktarvy in Treatment-Naïve Late Presenters With HIV-1 InfectionCompletedPhase 4Peking Union Medical College HospitalNCT04296695Written as B/F/TAF
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1Active, not recruitingPhase 3Gilead SciencesNCT06630286Written as B/F/TAF
See all 177 studies that test Emtricitabine →
Given in every arm · 37 — Emtricitabine is usual care beside what is tested
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTRecruitingPhase 3Africa Health Research InstituteNCT06250504Written as tenofovir disoproxil and emtricitabine
- Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult ParticipantsCompletedPhase 1Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT06278389Written as Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
- Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)CompletedPhase 3French National Agency for Research on AIDS and Viral HepatitisNCT00302822Written as emtricitabine/tenofovir
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With MenCompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT02720094Written as TDF/FTC tablets
- Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed ChildrenCompletedPhase 2/3Gilead SciencesNCT01854775Written as E/C/F/TAF
- Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected WomenActive, not recruitingPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT03164564Written as Oral TDF/FTC
- Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant PatientsCompletedPhase 4Fundacion Clinic per a la Recerca BiomédicaNCT03360682Written as Emtricitabine 200 MG
- DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young MenCompletedPhase 4Public Health Foundation Enterprises, Inc.NCT03771638Written as Emtricitabine / Tenofovir Disoproxil Oral Tablet
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing RegimenCompletedPhase 2/3Gilead SciencesNCT02285114Written as F/TAF
- Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent MalesCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04692077Written as Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
- Study of Novel Antiretrovirals in Participants With HIV-1CompletedPhase 1Gilead SciencesNCT05585307Written as B/F/TAF
- Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent FemalesCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04824131Written as Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
- Bone, Immunologic, and Virologic Effects of a Antiretroviral RegimenCompletedPhase 2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT01400412Written as Emtricitabine
- A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 YearsCompletedPhase 2Janssen Sciences Ireland UCNCT00799864Written as Emtricitabine
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionCompletedPhase 1/2SEARCH Research FoundationNCT02475915Written as Emtricitabine
- Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive AdultsCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00051831Written as Emtricitabine
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American ParticipantsCompletedPhase 3Gilead SciencesNCT03631732Written as B/F/TAF
- Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy VolunteersCompletedEarly Phase 1Indiana UniversityNCT03202511Written as Tenofovir disoproxil fumarate/Emtricitabine
- Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected AdultsCompletedPhase 1Gilead SciencesNCT03739866Written as B/F/TAF
- A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line TreatmentCompletedPhase 3Janssen-Cilag International NVNCT01709084Written as Emtricitabine
Showing 20 of 37.
As the comparator · 35 — what is tested is compared with Emtricitabine
- Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsRecruitingPhase 2Gilead SciencesNCT07841990Written as B/F/TAF
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07266831Written as BIC/FTC/TAF
- Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)RecruitingPhase 1/2Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT07711223Written as DTG+FTC/TAF
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or ObesityRecruitingPhase 3José Antonio Mata MarínNCT07075146Written as BIC/FTC/TAF
- Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral ExperienceRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07031063Written as Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyActive, not recruitingPhase 3ViiV HealthcareNCT05979311Written as Emtricitabine
- DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05705349Written as BIC/FTC/TAF
- Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)CompletedPhase 3Merck Sharp & Dohme LLCNCT04233879Written as BIC/FTC/TAF
- Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedActive, not recruitingPhase 2/3Gilead SciencesNCT06544733Written as Bictegravir/emtricitabine/tenofovir alafenamide
- Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedTerminatedPhase 2/3Gilead SciencesNCT06613685Written as Bictegravir/emtricitabine/tenofovir alafenamide
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT04223791Written as BIC/FTC/TAF
- Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]CompletedPhase 2Merck Sharp & Dohme LLCNCT04564547Written as BIC/FTC/TAF
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05630755Written as BIC/FTC/TAF
- A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06891066Written as BIC/FTC/TAF
- Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir AlafenamideCompletedPhase 4Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT04636437Written as Tenofovir alafenamide/emtricitabine
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight GainCompletedPhase 4Janssen Scientific Affairs, LLCNCT04442737Written as TAF/FTC FDC
- The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)CompletedPhase 2HIV Prevention Trials NetworkNCT01327651Written as Daily dosing
- A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)CompletedPhase 3ViiV HealthcareNCT01910402Written as Tenofovir/emtricitabine FDC
- Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TCTerminatedPhase 3Bristol-Myers SquibbNCT01620944Written as Tenofovir/Emtricitabine
- An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)CompletedPhase 3ViiV HealthcareNCT02831764Written as Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Showing 20 of 35.
Codes
What other systems call Emtricitabine · ClinicalTrials.gg INT006529
- MeSH (NLM) D000068679EmtricitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G70B4ETF4SEMTRICITABINEConfirmed FDA, NLM, Wikidata
- RxNorm 276237Confirmed FDA, Wikidata
- Wikidata Q422604emtricitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47509EmtricitabineOne source FDA
- DrugBank DB00879One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068679 | Emtricitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G70B4ETF4S | EMTRICITABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 276237 | — | Confirmed FDA, Wikidata |
| Wikidata | Q422604 | emtricitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47509 | Emtricitabine | One source FDA |
| DrugBank | DB00879 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.